| ASSET | QUARTER | % RETURN |
|---|---|---|
Edgewise Therapeutics (EWTX) | Q1 2021 | 20.37% |
Edgewise Therapeutics (EWTX) | Q2 2021 | -30.29% |
Edgewise Therapeutics (EWTX) | Q3 2021 | -22.5% |
Edgewise Therapeutics (EWTX) | Q4 2021 | -8.88% |
Edgewise Therapeutics (EWTX) | Q1 2022 | -34.06% |
Edgewise Therapeutics (EWTX) | Q2 2022 | -18.02% |
Edgewise Therapeutics (EWTX) | Q3 2022 | 23.46% |
Edgewise Therapeutics (EWTX) | Q4 2022 | -9.97% |
Edgewise Therapeutics (EWTX) | Q1 2023 | -25.89% |
Edgewise Therapeutics (EWTX) | Q2 2023 | 15.5% |
Edgewise Therapeutics (EWTX) | Q3 2023 | -24.7% |
Edgewise Therapeutics (EWTX) | Q4 2023 | 90.92% |
Edgewise Therapeutics (EWTX) | Q1 2024 | 66.88% |
Edgewise Therapeutics (EWTX) | Q2 2024 | -1.48% |
Edgewise Therapeutics (EWTX) | Q3 2024 | 48.36% |
Edgewise Therapeutics (EWTX) | Q4 2024 | -1.07% |
Edgewise Therapeutics (EWTX) | Q1 2025 | -17.76% |
Edgewise Therapeutics (EWTX) | Q2 2025 | -24.82% |
